Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: perera y. Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25. Mol Cell Biochem. 2008. PMID: 18575815 Clinical Trial.
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.
Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B. Perea SE, et al. Among authors: perera y. Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7. Mol Cell Biochem. 2011. PMID: 21735096 Clinical Trial.
Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma.
Cabrales-Rico A, de la Torre BG, Garay HE, Machado YJ, Gómez JA, Audain E, Morales O, Besada V, Marcelo JL, Reyes V, Perera Y, Perea SE, Reyes O, González LJ. Cabrales-Rico A, et al. Among authors: perera y. J Pharm Biomed Anal. 2015 Feb;105:107-114. doi: 10.1016/j.jpba.2014.11.043. Epub 2014 Dec 3. J Pharm Biomed Anal. 2015. PMID: 25546027
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D, González LJ, Zettl K, Wiśniewski JR, Yang K, Perera Y, Perea SE. Rosales M, et al. Among authors: perera y. Biomedicines. 2021 Jul 1;9(7):766. doi: 10.3390/biomedicines9070766. Biomedicines. 2021. PMID: 34356831 Free PMC article.
Positive effects of Phycocyanobilin on gene expression in glutamate-induced excitotoxicity in SH-SY5Y cells and animal models of multiple sclerosis and cerebral ischemia.
Gardón DP, Cervantes-Llanos M, Matamoros BP, Rodríguez HC, Tan CY, Marín-Prida J, Falcón-Cama V, Pavón-Fuentes N, Lemus JG, Ruiz LCB, Argudin TD, Donato GM, Perera Y, Yang K, Pentón-Rol G. Gardón DP, et al. Among authors: perera y. Heliyon. 2022 Jun 20;8(6):e09769. doi: 10.1016/j.heliyon.2022.e09769. eCollection 2022 Jun. Heliyon. 2022. PMID: 35800718 Free PMC article.
77 results